351
Participants
Start Date
March 26, 2017
Primary Completion Date
April 5, 2022
Study Completion Date
January 7, 2025
Nivolumab
Specified dose on specified days
Ipilimumab
Specified dose on specified days
Cabazitaxel
Specified dose on specified days
Prednisone
Specified dose on specified days
Local Institution - 0048, Vienna
Local Institution - 0059, Wahroonga
Local Institution - 0061, København Ø
Local Institution - 0029, Westmead
Local Institution - 0027, Gosford
Local Institution - 0031, Clayton
Local Institution - 0043, Woolloongabba
Local Institution - 0028, Southport
Local Institution - 0060, Odense
Local Institution - 0030, Elizabeth Vale
Local Institution - 0063, Aarhus N
Local Institution - 0062, Aalborg
Local Institution - 0001, New York
Local Institution - 0065, Lake Success
Local Institution - 0078, Albany
Local Institution - 0004, Marseille
Local Institution - 0023, Santiago Compostela
Local Institution - 0047, Allentown
Local Institution - 0036, Rostock
Local Institution - 0010, Philadelphia
Local Institution - 0052, Milan
Local Institution - 0020, Madrid
Local Institution - 0022, Madrid
Local Institution - 0021, Madrid
Local Institution - 0024, Málaga
Local Institution - 0067, Charleston
Local Institution - 0046, Marietta
Local Institution - 0038, Göttingen
Local Institution - 0041, Braunschweig
Local Institution - 0072, Parma
Local Institution - 0019, Herne
Local Institution - 0035, Wesel
Local Institution - 0018, Münster
Local Institution - 0071, Arezzo
Local Institution - 0076, Minneapolis
Local Institution - 0011, Chicago
Local Institution - 0009, Clermont-Ferrand
Local Institution - 0008, St Louis
Local Institution - 0005, Lyon
Local Institution - 0033, Tübingen
Local Institution - 0042, Nürtingen
Local Institution - 0002, Houston
Local Institution - 0079, Austin
Local Institution - 0053, Napoli
Local Institution - 0034, Munich
Local Institution - 0074, Tucson
Local Institution - 0075, Las Vegas
Local Institution - 0037, Nuremberg
Local Institution - 0003, Villejuif
Local Institution - 0077, Tigard
Local Institution - 0044, Montreal
Local Institution - 0032, Dresden
Local Institution - 0017, Jena
Local Institution - 0051, Terni
Local Institution - 0055, Krakow
Local Institution - 0066, Koszalin
Local Institution - 0054, Warsaw
Local Institution - 0026, Badajoz
Local Institution - 0025, Barcelona
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY